P&G Comfortable As "Niche" Rx Firm: Buys Clairol For Cash, Not Swap
Executive Summary
Procter & Gamble is comfortable with its position as a "niche" player in the pharmaceutical industry over the short term, CEO A.G. Lafley said during a May 21 analysts meeting discussing the acquisition of Clairol from Bristol-Myers Squibb.
You may also be interested in...
Bristol/DuPont Is Timely Deal: Will Disrupt Difficult 2002, Add To 2003
The Bristol/DuPont deal may offer Bristol-Myers Squibb a healthy dose of distraction heading through a difficult period of patent expirations.
Bristol/DuPont Is Timely Deal: Will Disrupt Difficult 2002, Add To 2003
The Bristol/DuPont deal may offer Bristol-Myers Squibb a healthy dose of distraction heading through a difficult period of patent expirations.
P&G Dantrium Bulk Manufacturing Practices Draw FDA Warning Letter
Procter & Gamble is speeding up its efforts to upgrade the manufacturing of bulk dantrolene at its Manati, Puerto Rico plant following an FDA warning letter.